Pfizer launches Sutent for gastric and renal cancers

Pfizer has launched Sutent (sunitinib malate), a tyrosine kinase inhibitor, for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) resistant or intolerant to imatinib and the treatment of advanced and/or metastatic renal cell carcinoma (MRCC) after failure of interferon alfa or interleukin-2.

Sunitinib is a highly selective molecule that inhibits multiple receptor tyrosine kinases, some of which are implicated in tumour growth, pathologic angiogenesis and metastatic progression of cancer.

In an open-label study of 97 patients with GIST, sunitinib was given in a four weeks on, two weeks off schedule until the disease progressed or patients were withdrawn for other reasons. At the end of the study the median time to disease progression was 34 weeks.

In a subsequent phase III placebo-controlled study involving 312 GIST patients with imatinib resistance or intolerance, sunitinib significantly prolonged the time to disease progression. In this study the median time to progression was 28.9 weeks compared with 5.1 weeks in the placebo group. At disease progression, treatment was unblinded and patients in the placebo group were offered crossover to sunitinib, while those in the treatment group were allowed to continue. The difference in overall survival was statistically in favour of sunitinib, with the risk of death double in the placebo group. The percentages of deaths were 14% for sunitinib as opposed to 25% for placebo. However, at the time of analysis the data were not mature enough to determine overall survival benefit.

In a phase II study of 63 patients with MRCC, sunitinib was given on a four weeks on, two weeks off schedule. The primary efficacy endpoint was taken as the objective response rate based on RECIST. In this study the objective response rate was 36.5% and the median time to progression was 37.7 weeks. In a similar open-label multicentre study of 106 patients, the objective response rate was 38% but the duration of response and overall survival had not been reached by the time of analysis.

Further information: Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Tel: (01304) 616161.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases